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ABSTRACT 
The purpose of this study was to evaluate the efficacy of a 
free nicotine- patch therapy for smoking cessation in Saudi 
smokers. A single centered prospective study was carried out in 
a charity clinic for smoking cessation in Riyadh, Saudi Arabia.  A 
total of 31 subjects who attended the smoking cessation clinic 
from June 2014 to August 2014 were studied. All participants 
were male and their mean age was 31.1±6.4 years. The duration 
of history of smoking was 12.9±6.8 years. The nicotine- patch 
therapy outcomes were measured at baseline and at 6 weeks 
after using nicotine- patch therapy. At base line the number of 
cigarettes per day was 27±10 and carbon monoxide (CO) level 
was 20.2±8.3. The analyzed statistics revealed that there were 
significant decreased in the number of cigarette per day 
(p=0.001) and Carbon Monoxide (CO) level (p=0.001) over 6 
weeks of nicotine- patch therapy. After 6 weeks of therapy, 
abstinence rate was 58 % (verified by CO level) and no serious 
adverse reactions were documented. The most common side 
effects were nausea, headache and local irritation sings. In 
addition, our finding revealed that smokers were likely to suffer 
from withdrawal symptoms following trying to quit. These 
withdrawal symptoms include sleep disturbance, loss of 
concentration and weight gain as well as irritability. Results of 
this study show that free nicotine-patch therapy is an effective 
measure for smoking cessation in Saudi population. 
 
Keywords: nicotine patch therapy, smoking cessation clinic, side effects 
 
INTRODUCTION 
Smoking is major public health problem 
and a condition that leads to increase morbidity 
and mortality (Fiore et al., 2008). The World 
Health Organization (WHO) statistics showed 
more than 5 million of people killed per year 
due to tobacco use (WHO, 2014). It has been 
postulated that the number of tobacco- related 
deaths worldwide in the year 2020 could 
increase to 8.4 million (Al-Rifi, 2004). 
Complications related to smoking are cancer, 
heart disease, stroke, and chronic obstructive 
pulmonary disease (Preechawong et al., 2011).  
Smoking in Saudi Arabia influenced by 
cultural and environment; the country has 
history of smoking more than 50 years (Al-Rifi, 
2004).  Patterns of smoking in Saudi population 
include cigarette and other smoking paste-
mixture such as Jurake and mehassel (Al-Arifi et 
al., 2006). Consequently, smoking is major 
public health issue in Saudi Arabia, as it has 
been estimated that 2.4 -52.4% of Saudi Arabia 
are smoker (Bassiony, 2009). Among 
adolescents, the prevalence of current smoking 
ranges from 15%-30%.(Jarallah et al., 1996; 
Lam et al., 2005).  In addition, smoking is not 
only dangerous to people but contributing to 
be social cost. Saudi Arabia spends around 
$315 million for purchasing tobacco every year 
(Bassiony, 2009). 
The most effective intervention of 
reducing serious complications in smokers is to 
quit smoking (Lam et al., 2005). Nicotine- patch 
therapy is an effective pharmacological assist 
for smokers attempting to quit, and it has been 
evidenced as first line treatment for smoking 
cessation (Xiao et al., 2014). However, limited 
smoking cessation studies established in Asian 
populations have been established in China, 
and Taiwan (Lam et al., 2005; Hsueh et al., 2010, 
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Xiao et al., 2014). In addition, there is little data 
from the Middle East namely Kingdom of 
Saudi Arabia focusing on ethnic differences in 
tobacco dependence, smoking cessation and 
behavioral aspects of quitting smoking.  
Free nicotine patch program has shown 
significant impact in helping certain ethnicity to 
quit smoking achieving an abstinence rate of 
26.7% in 4 months follow-up period among 
Asian American population in the United States 
(Shelley et al., 2010). Several charity and free 
smoking cessation programs and clinics are 
available in Saudi Arabia; however, to best of 
our knowledge, no study was conducted to 
evaluate the efficacy, safety and tolerability of 
nicotine- patch therapy programs. Therefore, 
this study was done to investigate the 
effectiveness of a free nicotine- patch therapy 
for smoking cessation in Saudi Arabia. 
 
MATERIAL AND METHODS 
The current study was a single centered 
prospective study to evaluate the efficacy of a 
free nicotine-patch therapy in Saudi smokers 
through the period from June 2014 to August 
2014. In addition to the efficacy, the safety of 
nicotine patch was assessed. The subjects were 
enrolled from a charity clinic for smoking 
cessation in Riyadh, Saudi Arabia. Any Saudi 
smoker who ages 18 years or older and smokes 
at least 10 cigarettes per day was included in the 
study. Subjects were excluded if subjects: (1) 
were using tobacco-containing products other 
than cigarettes;(2) were pregnant women; (3) 
had cardiovascular diseases; (4) used nicotine 
NRT within 6 months; (5) had a level of carbon 
monoxide less than 10 parts per million (ppm); 
(5) were diagnosed with psychiatric condition. 
Data collected included: socio-demographic 
data, physical examination, medical history and 
vital signs assessed by the clinic physicians, and 
analysis of an expired carbon monoxide (CO) 
sample. All these date were taken from patient's 
profile.   
 
Intervention  
The smoking cessation program was a 6-
week program of free nicotine-patch therapy. 
Every subject received 21mg per day during the 
first and second week, 14 mg per day during 
the third and fourth week and 7mg per day 
during the fifth and sixth week.  Proper 
application and usage of nicotine patch were 
delivered to all our study's subjects. The ethical 
approval was obtained from King Saud 
University College of Pharmacy.  All 
participants were informed and briefed on the 
study. Then, they signed a written consent and 
scheduled for a medical screening examination. 
 
Measures 
Subjects attended the clinic weekly. 
Evaluations were done at baseline before the 
intervention of nicotine -patch therapy and at 
the sixth week visit after completing the 
treatment regimen. At baseline, data on number 
of cigarettes per day, CO levels, smoking 
history and patients’ demographic data were 
obtained. The data collections were repeated 
after 6 weeks of receiving nicotine- patch 
therapy. The outcome of the nicotine-patch 
therapy was measured as changes in the 
number of cigarettes per day, the CO level, and 
abstinence rates. In addition, the adverse events 
were assessed by interviewing the participants. 
 
Safety  
The adverse events were assessed by 
interviewing the participants during their 
weekly visits. The researchers also reviewed the 
patient records to determine any adverse events  
 
Efficacy  
Abstinence rates: Smoking abstinence 
was determined by self-reported cigarette use 
and verified with a CO level lower than 10 
ppm. The assessment of quit smoking included 
point-prevalence abstinence. The point-
prevalence rate of abstinence measured at the 
6th-week right after the treatment. Point-
prevalence abstinence refers to the percentage 
of individuals   who were not smoking during 
the previous 7 days (Chen et al., 2002). 
CO levels: The CO levels were assessed 
by having subjects take a deep breath and hold 
it for 15 seconds before exhaling into a CO 
monitor (Bedfont Micro Smokerlyzer). Levels 
lower than 10 ppm was indicator of abstinence.  
 
Statistical analysis 
All the data were transferred to the 
spreadsheet of SPSS version 21 for analysis. 
Descriptive data were presented as numbers, 
frequencies, percentages, means and standard 
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deviations. Wilcoxon test was used to analyse 
the significance of variations before and after 
intervention. 
 
RESULTS AND DISCUSSION  
Baseline characteristics 
A total of 31 smokers who fulfilled the 
inclusion criteria were included in the study. 
The characteristics of participants are shown     
in Table I.  All participants were male. The 
mean age of participants was 31.1±6.4 years. 
The duration of history of smoking was 
12.9±6.8 years.  The number of cigarettes             
per day was 27±10. The CO level was 
20.2±8.3. 
 
The outcomes of nicotine patch 
The number of cigarettes per day 
Reduction of the amount of cigarette 
smoking per day over the 6 weeks period 
summarized (Table II). The mean number           
of cigarette at baseline was 27 cigarette                     
per day (SD=10) and at 6 weeks was 
12.3(SD=16.3). There was significant reduction 
in the number of cigarette per day at base       
line and 6 weeks (p=0.001) from the 
intervention.   
 
CO level 
The CO level is an important measure of 
the efficacy of nicotine-patch therapy. The 
mean scores of the CO level pre-intervention 
and after the intervention was 20.2(SD=8.3), 
11.1(SD=12.6) respectively (Table II). There         
was significant reduction in CO level after 
inter-vention of nicotine-patch therapy 
(p=0.001). 
Abstinence rates 
The point-prevalence rates of abstinence 
from smoking, as verified by CO levels showed 
that subjects were abstinent at 58 % at 6 weeks 
(18 of 31 subjects). 
 
Adverse reactions 
The majority of adverse reactions 
reported during the period of study were 
headache (19.3%), followed by itching (16.1) 
and redness (12.9).  Table 3 shows others 
adverse reactions were reported.  In addition 
only one participant of non quit smokers had 
adverse reaction namely headache.   
 
Withdrawal symptoms  
Withdrawal symptoms of smoking were 
sleep disturbance (35.4 %) , irritability (35.4 %) 
and loss of concentration (48.4%) (Table IV).   
The present study evaluated the 
effectiveness and safety of nicotine-patch 
therapy in a population of Saudi Arabia. To our 
knowledge this was first smoking cessation 
carried out in Saudi Arabia smokers. The 
finding of this study revealed that nicotine- 
patch therapy for smoking cessation appeared 
to be safe and effective. These findings were 
consistent with a study evaluated the efficacy a 
free nicotine-patch program among Chinese 
American smokers living in New York City 
(Shelley et al., 2010). A total of 375 subjects 
from two community-based organizations were 
enrolled to receive free nicotine patch therapy. 
Baseline and 4-months follow-up survey were 
used to determine the abstinence rate. The 
abstinence rate at 4 months was 26.7%.  One of 
the main outcomes of smoking cessation is 
Table I. The characteristics of participants (n = 31) 
 
Variables  Mean (SD) n (%) 
 Age in years  31.1(6.4)  
Gender  
   Male  
  
31(100) 
Education level  
   High school  
   University  
  
14(45.2) 
17(54.8) 
The duration of history of smoking in eyras  12.9(6.8)  
 The number of cigarettes per day   27(10)  
Carbon monoxide (CO) level  20.2(8.3)  
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abstinence rate.  The abstinence rate of this 
study was 58% at 6 weeks.  The abstinence rate 
had a high effect in smoking cessation through 
6 weeks period of nicotine- patch therapy. Our 
higher abstinence rate was consistent with 
other studies (Chou et al., 2004; Paoletti et al., 
1996), suggesting that the nicotine patch 
approach promoted smoking cessation in Saudi 
pupation.  
This study found positive reduction in 
the number of cigarettes over 6 weeks. This 
demonstrated that nicotine patch therapy 
significantly reduce the daily cigarettes 
smoking. In addition, the significant reduction 
in CO level supported the reduction in daily 
cigarette smoking. The result supports the 
outcomes of previous studies that nicotine -
patch therapy was effective in smoking 
reduction verified by reduction in CO level s 
and number of cigarette smoking per day 
(Joseph et al., 1996; Chou et al., 2004; Batra et al., 
2005; Xiao et al., 2014).  
This study confirmed the safety of 
nicotine –patch therapy amongst the Saudi 
smokers as reflected from the low prevalence 
of mild symptoms tolerated by Saudi smokers.  
This study reported 32.2% of side effect 
including systemic events (headache, nausea) 
and dermatitis disorders. However, our finding 
are much lower than those reported (50%) in 
USA (Transdermal Nicotine Study Group, 
1991).   Moreover, a similar study was carried 
out in china aimed to assess safety of nicotine 
patch in Chinese smokers    reported that 26.3 
% of subjects had gastrointestinal side effects 
(Xiao et al., 2014). This study showed that the 
most common withdrawal symptoms were 
sleep disturbance, loss of concentration, weight 
gain and irritability. All these withdrawal 
symptoms are consistent with several previous 
Table II. The outcomes of nicotine patch therapy (n = 31) 
 
Smoking status Variables 
Pre intervention 
Mean (SD) 
Post intervention 
Mean (SD) 
P* 
value 
Quit smoking CO level  
Number of cigarette 
16.3 (3.8) 
22 (4) 
2.8 (2.1) 
0.0 
P=0.001 
P=0.001 
Continue smoking  CO level  
Number of cigarette 
25.6 (10.1) 
33 (12) 
22.8 (11.9) 
29 (13) 
P=0.067 
P=0.017 
Total  CO level  
Number of cigarette 
20.2 (8.3) 
27 (10) 
11.1 (12.6) 
12 (16) 
P=0.001 
P=0.001 
* Wilcoxon 
 
Table III. Numbers of participants reporting adverse reaction events 
 
Adverse events n (%) 
Redness  4 (12.9) 
Itching   5 (16.1) 
Headache   6 (19.3) 
Nausea  4 (12.9) 
Others 2 (6.4) 
 
Table IV. Numbers of participants reporting withdrawal symptoms of smoking 
 
Withdrawal symptoms  n % 
Sleep disturbance  11(35.4) 
Weight gain  8(25.8) 
Irritability  11(35.4) 
Loss of concentration  15(48.4) 
Others  2(6.4) 
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studies (Dorothy et al.,1984; Hajek et al.,1989; 
Zhang et al., 2006; Tomson et al., 2006). 
Although the findings of study are 
promising, the efficacy and safety of nicotine 
patch therapy in Saudi population, it has some 
limitations.  One of the limitations is the 
participation was restricted to male smokers 
and limited by small size who attended the 
Naqa Charity Clinic. Therefore, the results of 
this study could only represent the situation in 
Riyadh city. Another limitation is the short-
term follow-up of the smoking cessation and 
reducing rates. Thus, an extended time follow-
up may be needed to demonstrate longitudinal 
benefits from the nicotine-patch therapy.  
 
CONCLUSION 
This study reported initial data on the 
safety and efficacy of nicotine patch therapy in 
Saudi population. The main contribution of this 
study showed that nicotine patch therapy can 
be an important adjunct to smoking cessation 
in Saudi smokers. Six –week abstinence rate 
showed higher effect after the use of nicotine-
patch therapy. 
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